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Abstract
Aim of the study: We evaluated the impact of patient age and time from collapse to return of spontaneous circulation (ROSC) on the prognostic
accuracy of neuron specific enolase (NSE) after out-of-hospital cardiac arrest (OHCA).
Methods: Using electrochemiluminescence immunoassay, we measured serum concentrations of NSE in 249 patients who were admitted to intensive
care units after resuscitation from OHCA. In each quartile according to age and time to ROSC, we evaluated the ability of NSE at 48 h after OHCA to
predict poor outcome (Cerebral Performance Category 3–5) at 12 months.
Results: The outcome at 12 months was poor in 121 (49%) patients. The prognostic performance of NSE was excellent (area under the receiver
operating characteristic curve, AUROC, 0.91 [95% confidence interval, 0.81–1.00]) in the youngest quartile (18–56 years), but worsened with increasing
age, and was poor (AUROC 0.53 [0.37–0.70]) in the oldest quartile (72 years or more). The prognostic performance of NSE was worthless (AUROC 0.45
[0.30–0.61]) in the quartile with the shortest time to ROSC (1–13 min), but improved with increasing time to ROSC, and was good (AUROC 0.84 [0.74–
0.95]) in the quartile with the longest time to ROSC (29 min or over).
Conclusion: NSE at 48 h after OHCA is a useful predictor of 12-month-prognosis in young patients and in patients with a long time from collapse to
ROSC, but not in old patients or patients with a short time to ROSC.
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Introduction
After cardiac arrest and resuscitation, prognostication is challeng-
ing.1,2 In addition to clinical neurological examination, imaging and
neurophysiological studies, certain biomarkers, particularly neuron
specific enolase (NSE), are considered useful.3–7 Sedative medi-
cations affect clinical examination and electroencephalography
(EEG) but not biomarkers.7 Hypoxic brain injury increases blood
NSE concentrations8 and international guidelines recommend the use
of NSE as one part of multimodal prognostication.6
However, also other factors than hypoxic brain damage may
elevate the NSE concentration4,8–14 and a good outcome is possible
despite high concentrations.8,15–17 In addition, NSE concentrations
can remain low despite severe brain damage.15
It is not known whether age affects the prognostic ability of NSE
after cardiac arrest. Moreover, the time from collapse to the return of
spontaneous circulation (ROSC) probably affects the severity of
hypoxic-ischemic brain injury, a typical cause of death after cardiac
arrest,18 but it is unknown if this affects the prognostic value of NSE.
We aimed to evaluate the impact of the patient’s age and time from
collapse to ROSC on the ability of NSE to predict poor long-term outcome
in patients resuscitated from out-of-hospital cardiac arrest (OHCA).
Methods
Study population
This study is a sub-study of the FINNRESUSCI study.19 In brief, the
FINNRESUSCI study prospectively collected data on 504 adult
patients who were treated in 21 Finnish intensive care units (ICUs)
after OHCA between March 1st, 2010, and February 28th, 2011. In the
current study we included 249 unconscious patients, for whom blood
samples were available. The FINNRESUSCI study protocol was
approved by the Ethics Committee of Helsinki University Hospital and
by each participating hospital.
We assessed neurological outcome according to the Cerebral
Performance Category (CPC)20 at 12 months after cardiac arrest. We
determined good outcome as sufficient neurological function for
managing activities of daily living independently (CPC 1–2) and poor
outcome as severe neurological deficits or death (CPC 3–5). The
cause of cardiac arrest (cardiogenic or other) was determined with
clinical criteria. We chose death in hospital as a secondary outcome.
Data collection
Patient data were collected by using Internet-based case report forms.
Data on previous state of health was collected from the patients
medical history and mortality data were obtained from Statistics
Finland. Neurological status of all patients at 12 months after cardiac
arrest was assessed by phone contact between the patient and a
specialist in neurology who was blinded to treatment details. A
structured interview to determine the Pittsburgh Cerebral Perfor-
mance Category (CPC) was used.
Blood sampling and biomarker analysis
Blood samples were taken at 24 and 48 h after cardiac arrest. The
blood sample was allowed to clot at room temperature for 60 min, after
which it was centrifuged and the obtained serum stored at 70 C.
Serum concentrations of NSE were measured with a commercially
available electrochemiluminescence immunoassay (Roche Diagnos-
tics GmbH, Mannheim, Germany) in April 2015. All analyses were
made in the same laboratory. The range of measurements was 0.05–
370 mg/l (or up to 740 mg/l for 2-fold diluted samples) and the range of
normal values was 0–16.3 mg/l. The intra and inter assay coefficients
of variation were < 3.9% and < 3.2%, respectively. We considered a
concentration of 500 mg/l or higher of free haemoglobin as an indicator
of significant haemolysis.3 In line with a real-life situation in Finland, we
included all blood samples to the study regardless of the amount of
haemolysis.
Statistical analysis
We present continuous data as medians with interquartile ranges
(IQRs) and categorical data as absolute numbers with percentages
(95% confidence intervals [CIs]). We tested normality of distribution
with the Kolmogorov–Smirnov test. We used the independent samples
t test to compare continuous data with normal distributions. When the
distribution was not normal, we used the Mann–Whitney U test or the
Kruskal–Wallis test, as appropriate. We compared categorical
variables by using Pearson’s Chi test or Fisher’s exact test, as
appropriate.
To assess the ability of NSE to discriminate between patients with
poor outcome (CPC 3–5) and those with good outcome (CPC 1–2), we
calculated areas under the receiver operating characteristic curves
(AUROCs)21 with 95% CIs. We defined values <0.7 as poor, values of
0.7–0.8 as satisfactory, 0.8–0.9 as good and values >0.9 as excellent.
In addition to NSE levels at 24 h and 48 h after cardiac arrest, we also
studied the change in NSE between 24 h and 48 h after cardiac arrest.
We determined IQRs for patient’ ages and the times from collapse to
ROSC, and for every quartile we calculated the AUROC for NSE at
48 h. We compared AUROCs by using the bootstrap method. Based
on the sensitivity and specificity for different cut-off values, we
selected cut-offs using the Youden index.22,23We also determined the
cut-off value for 99% specificity. We calculated the sensitivity,
specificity, positive predictive value (PPV) and positive likelihood ratio
(LR+) for these cut-off values.
We used logistic regression analysis to create a baseline
multivariate model to predict poor outcome. We evaluated the
predictive value of this model by determining the AUROC. We also
assessed the continuous Net Reclassification Improvement (NRI)
achieved by the addition of NSE into the baseline model. We assessed
event NRI (NRIe) and non-event NRI (NRIne). NRIe is calculated as
[(the number of individuals with the predicted event, i.e. poor outcome,
given a higher risk after addition of NSE) — (the number of individuals
with the event given a lower risk)]/[the number of individuals with the
event]. Likewise, NRIne is the net proportion of individuals without the
event given a lower risk. The overall NRI is the sum of NRIe and NRIne.
The theoretical range of values for both NRIe and NRIne is–1 to +1,
and that of the overall NRI is –2 to +2. 24,25
In addition, we determined the Integrated Discrimination Improve-
ment (IDI) achieved by the addition of NSE into the baseline
multivariate model. IDI measures not only the direction of the change
in probability with the addition of new information, but also the
magnitude of the change. We calculated event IDI (IDIe) for patients
with poor outcome as [(mean probability of poor outcome with
baseline model + NSE) – (mean probability of poor outcome with
baseline model)] and non-event IDI (IDIne) for patients with good
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outcome as [(mean probability of poor outcome with baseline model)–
(mean probability of poor outcome with baseline model + NSE)]. IDI is
the sum of IDIe and IDIne. The theoretical range of IDIe and IDIne is–1
to +1 and that of IDI is –2 to +2. 24,26
We considered p values <0.05 as significant. We made the
analyses with SPSS version 21 (SPSS, Chicago, IL, USA) and R
version 3.1.1.
Results
In total, 249 OHCA patients were included in the study (Fig. 1). Blood
samples at 48 h were available for 220 patients. Because the consent
was not available for all patients at 24 h, samples from this time point
are missing for seven patients. The initial rhythm was shockable in 177
(71%) patients. The aetiology of the arrest was cardiac in 199 (79.9%)
patients. Targeted temperature management was used in 193
(77.5%) patients. The baseline characteristics of the study population
are presented in Table 1.
Patient outcomes and prognostic ability of NSE
Overall, 121 patients (49%) had a poor outcome at 12 months. The
median NSE concentration at 24 h was 12.9 mg/l (IQR, 7.6–23.6) in
patients with poor outcome and 8.7 mg/l (5.9–13.4) in those with good
outcome (p < 0.001). The median NSE concentration at 48 h was
17.9 mg/l (8.1–56.4) in patients with poor outcome and 8.2 mg/l (5.9–
12.1) in those with good outcome (p < 0.001). The ability to predict
poor outcome was better for NSE at 48 h (AUROC 0.72 [0.65–0.80)])
than NSE at 24 h (AUROC 0.65 [0.58–0.72]), p = 0.005.
The AUROC for the change in NSE concentration between 24 h
and 48 h after cardiac arrest was 0.70 (0.63–0.78[p < 0.001]), which
was not significantly different from the AUROC of NSE at 48 h
(p = 0.489).
Among those 29 patients, for whom blood samples at 48 h were not
available, poor outcome occurred in 23 patients (79.3%), 13 of whom
diedbeforethe 48 htimepoint.For these 29patients, the concentrations
of NSE at 24 h were 15.3 mg/l (4.8–47.9) for patients with poor outcome
and 6.3 mg/l (2.9–12.5) for those with good outcome.
For three patients, significant haemolysis was found. For two of
those patients, with NSE concentrations 36.0 mg/l and 37.0 mg/l,
Fig. 1 – Flowchart of the study population.
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respectively, at 48 h, CPC was 1–2. For one patient, with an NSE
concentration of 6.8 mg/l at 48 h, CPC at 12 months was 5 (death).
Cut-off values
Based on the Youden index, the cut-off value for NSE at 48 h as a
predictor of poor outcome at 12 months was 20 mg/l. With this cut-off,
sensitivity was 50%, specificity 92.6%, PPV 84.5% and LR + 6.8 (3.5–
13.1) (p < 0.001). When we required a 99% threshold for specificity,
we obtained the cut-off 37 mg/l (with sensitivity 35.7%, PPV 97.2%,
LR + 43.6 [6.1–312.4]) (p < 0.001). A specificity of 100% was obtained
with the cut-off value 68 mg/l (corresponding sensitivity 17%). Cut-off
values for specificities 95–100% for NSE at 48 h are presented in
Supplementary material, Table S1.
The Youden index-basedcut-offvalues forNSE48 haccording to age
and time to ROSC are presented in Supplementary material, Table S2.
The value of NSE in different age groups
The difference in NSE concentrations between patients with poor
outcome and those with good outcome was most remarkable in the
youngest quartile, whereas there was no statistically significant
difference in the oldest quartile. Distributions of NSE concentrations at
48 h for patients with poor outcome and for those with good outcome,
stratified according to age quartiles, are presented in Fig. 2.
The ability of NSE at 48 h to predict poor outcome in different age
groups ispresented inTable 2. The abilityofNSE at48 h topredict death
in hospital is presented in the Supplementary material, Table S3.
The value of NSE in different groups according to time to
ROSC
Distributions of NSE concentrations at 48 h for patients with poor and
for those with good outcome, stratified according to time to ROSC
quartiles, are presented in Fig. 3. The ability of NSE at 48 h to predict
Fig. 2 – Distribution of NSE concentrations (mg/l) at 48 h
for the patients with good (Cerebral Performance Cate-
gory, CPC 1–2) and poor (CPC 3–5) outcome in quartiles
according to age.
Boxplot figures; each box showing the interquartile
range, with a horizontal line inside the box showing
the median value; bars showing the range of values
except outliers (circles and stars), defined as values
more than 1.5 box lengths from the edge of the box.
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poor outcome in different groups according to time to ROSC is
presented in Table 2. The prognostic value was poor in the first quartile
(1–13 min), but improved with increasing time to ROSC, and was good
for patients with the longest time to ROSC (29 min).
The ability of NSE at 48 h to predict death in hospital in different
quartiles according to time to ROSC is presented in the Supplemen-
tary material, Table S3.
The main results remained essentially unchanged after exclusion
of the patients with haemolytic blood samples (Supplementary
material, Table S4).
The value of NSE in addition to other prognostic data
Our baseline risk prediction model including age, time to ROSC, initial
rhythm and Simplified Acute Physiology Score (SAPS) II points27
without age points had an AUROC of 0.81 (0.75–0.86) for predicting
poor outcome at 12 months. When 48 h NSE was added to this model,
the AUROC increased to 0.84 (0.79–0.89) (p = 0.021).
Regarding different age groups, adding NSE to the baseline risk
prediction model improved the AUROC only for the youngest patients
(18–56 years) (p = 0.013).
Considering different times to ROSC, adding NSE to the baseline
model improved the AUROC only for patients with longest time to
ROSC (29 min or more) (p < 0.001).
AUROC, NRI and IDI data for all patients and according to age and
time to ROSC quartiles are presented in Table 3.
NSE analyses were available in 9 of 21 participating hospitals at
the time of the FINNRESUSCI study. These hospitals treated 35.3% of
the study patients. The prognostic ability of NSE was dependent on
age and time to ROSC in both hospital groups (Supplementary
Tables S5 and S6).
Discussion
The main finding of our study is that the ability of NSE to predict one-
year outcome was dependent on both the patient’s age and the time
from collapse to ROSC. In young patients, NSE at 48 h had an
excellent predictive value, whereas the predictive value was poor in
the oldest patients. For patients with a short time from collapse to
ROSC, NSE at 48 h was not able to predict outcome, but it showed a
good predictive ability for patients with a long time to ROSC. These
findings are important as NSE is one of the parameters commonly
used in prognostication of patients resuscitated from cardiac arrest.
Further refinement of the use of NSE by identifying appropriate and
inappropriate patient groups is of great importance.
We suggest that there may be a plausible explanation for our
findings: NSE is a marker of neurological injury, but it may not be able
to predict a poor long-term prognosis that is caused by other factors
than hypoxic brain injury. For young patients, poor outcome after
cardiac arrest is often associated with hypoxic brain damage, whereas
poor long-term outcome in elderly patients may often be influenced by
other factors (e.g. heart failure, pulmonary or renal disease, infirmity),
i.e. factors that may not be reflected by post-resuscitation NSE levels.
For patients who die after initially successful resuscitation, hypoxic
brain injury is the most common cause of death, but deaths because of
circulatory failure also occur frequently.28
In the normal population, NSE levels do not vary significantly in
different ages.29 However, in patients with Alzheimer’s disease, NSE
concentrations in serum tend to decrease with increasing severity of
brain atrophy.30 It might be possible that Alzheimer’s disease and
other neurodegenerative disorders that are more common among the
old than in younger people may cause loss of neuronal tissue, which
might decrease the response of increasing NSE concentrations after
hypoxic brain injury.
In addition to age, the time from collapse to ROSC influenced the
ability of NSE to predict poor outcome. NSE at 48 h showed good
predictive ability for patients with a long time to ROSC, but not for those
with a short time to ROSC. A possible explanation is that for cardiac
arrest patients with a long time to ROSC, the cause of poor outcome is
often hypoxic brain injury that typically causes high NSE concen-
trations, whereas a poor outcome despite a short time to ROSC may
not be caused by hypoxic encephalopathy, but rather the underlying
conditions responsible for the cardiac arrest. In the study by
Fig. 3 – Distribution of NSE concentrations (mg/l) at 48 h for the patients with good (Cerebral Performance Category,
CPC 1–2) and poor (CPC 3–5) outcome in quartiles according to time from collapse to ROSC.
Boxplot figures; each box showing the interquartile range, with a horizontal line inside the box showing the median
value; bars showing the range of values except outliers (circles and stars), defined as values more than 1.5 box lengths
from the edge of the box.
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Table 3 – Multivariate models to predict poor outcome at 12 months (A). Area under receiver operating characteristic curve (AUROC), Net Reclassification
Improvement (NRI) and Integrated Discrimination Improvement (IDI) for all patients and stratified according to age and time to ROSC (B).
OR (95% CI) p
Agea 1.045 (1.018–1.074) 0.001
ROSCa 1.076 (1.042–1.112) <0.001
Witnesseda 0.319 (0.101–1.011) 0.052
Shockablea 0.309 (0.152–0.627) 0.001
*SAPSIIa 1.041 (1.019–1.064) <0.001
NSE48b 1.055 (1.025–1.085) <0.001
AGE, years Time to ROSC, min
ALL 18–56 57–63 64–71 72 1–13 14–20 21–28 29
AUROC (95% CI) Baseline model 0.81 (0.75–0.86) 0.82 (0.71–0.93) 0.84 (0.74–0.95) 0.82 (0.71–0.94) 0.68 (0.52–0.84) 0.72 (0.58–0.86) 0.80 (0.68–0.91) 0.83 (0.71–0.95) 0.71 (0.54–0.87)
Baseline model +NSE 48 h 0.84 (0.79–0.89) 0.88 (0.79–0.97) 0.88 (0.79–0.97) 0.84 (0.73–0.95) 0.67 (0.52–0.82) 0.68 (0.54–0.83) 0.82 (0.71–0.93) 0.85 (0.75–0.96) 0.90 (0.82–0.99)
p value for difference 0.021 0.013 0.226 0.665 0.819 0.100 0.453 0.561 0.001
NRI Continuous 0.394 0.773 0.516 0.457 0.332 0.491 0.244 0.628 1.140
NRIe 0.082 0.217 0.143 0.040 0.379 0.467 0.444 0.067 0.257
NRIne 0.476 0.556 0.659 0.417 0.047 0.024 0.688 0.695 0.883
IDI IDI 0.032 0.141 0.035 0.017 0.077 0.059 0.000 0.039 0.228
IDIe 0.010 0.078 0.017 0.035 0.041 0.039 0.046 0.013 0.036
IDIne 0.041 0.063 0.052 0.051 0.035 0.020 0.047 0.051 0.192
ROSC, return of spontaneous circulation;Witnessed, witnessed cardiac arrest, Shockable, shockable initial rhythm (ventricular fibrillation or ventricular tachycardia); SAPSII, Simplified Acute Physiology Score II; NSE48, NSE
concentration at 48 h after cardiac arrest; AUROC, the area under the receiver operating characteristic curve; NRI, net reclassification improvement; NRIe, event NRI; NRIne, non-event NRI; IDI, integrated discrimination
improvement; IDIe, event IDI; IDIne, non-event IDI.
*SAPSII without age points.
a Variables in baseline model. Calculated with logistic regression for 220 patients for whom NSE at 48 h was available.
b NSE at 48 h added to the baseline model.
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Streitberger et al. on 1053 resuscitated patients, the cause of death
was other than hypoxic brain injury for the majority of patients who died
even though the NSE concentration was 17 mg/l or lower.4
In our study, the cut-off obtained with the Youden method was
20 mg/l, whereas it was 29 mg/l in the study by Stammet et al. For a
99% threshold of specificity, the cut-off was 37 mg/l, as compared to
68 mg/l in the study by Stammet et al. Requiring 100% specificity
results in low sensitivity, which limits the clinical use of biomarkers,
and a lower specificity for cut-off values has been proposed by
Stammet et al.31
Optimal cut-off values for NSE at 48 h to predict poor neurological
outcome have varied between 25 and 97 mg/l in different studies.4,11,15
There are severalpossible explanations for the largevariation: thereare
differences in laboratory methods,32 in patient case-mix,4,15 in
definitions of poor outcome15 and in the time between the cardiac
arrest and the assessment of neurological outcome.3–4,16,33–36
Commonly, outcome has been determined at six months after cardiac
arrest,3,16,36 whereas we assessed outcome at 12 months.
For some individuals, NSE concentrations after cardiac arrest and
resuscitation may be high although their prognosis is good.8,15–17
Also, ischaemic or haemorrhagic stroke or traumatic intracerebral
bleeding increase the serum NSE values, but high levels do not
exclude the possibility of a good outcome.12–14 In addition,
extracerebral sources of NSE may cause bias: high NSE concen-
trations have been found in association with several diseases,
including small cell lung cancer9 and many neuroendocrine tumors.37
Therefore, it is advisable to avoid decisions about futility of care on the
basis of NSE concentrations alone. Nevertheless, NSE is a useful part
of multimodal prognostication based on repeated clinical examination,
electrophysiological studies and brain imaging.6–7 However, it is
important to realise that haemolysis may increase NSE concen-
trations,4,10 and NSE measurements from haemolytic blood samples
must not be used for prognostication.
Strengths and limitations
Our study has a number of strengths. This was a nationwide
multicentre study with 249 patients. All blood samples were analysed
in the same laboratory at one time and long-term neurological
outcome was defined by an experienced neurologist blinded to the
NSE results.
There are also limitations. Firstly, we did not have blood samples
from all FINNRESUSCI study patients. In fact, there was a difference
in the proportion of shockable rhythms between our study (71.1%) and
the original FINNRESUSCI study (56.8%) and in the proportion of
cardiac aetiology of CA (79.9% vs. 66.3). Accordingly, the proportion
of patients with good outcome was higher in our study (51%) than in
the original FINNRESUSCI study (38.5%), indicating some degree of
selection bias. Secondly, we do not know the best CPC or the cause of
death of our study patients. Third, the number of patients in the
subgroups was rather small.
Conclusions
In this observational study, we found that the ability of NSE at 48 h to
predict long-term outcome after resuscitation from OHCA was good
for young patients and for patients with a long time from collapse to
ROSC, but poor for the oldest patients and for those with a short time to
ROSC. If these findings are confirmed in other studies, they should be
taken into account when prognostication guidelines are updated.
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